PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

被引：0
|
作者：
Verstovsek, S. [1 ]
Vannucchi, A. M. [2 ]
Platzbecker, U. [3 ]
Cervantes, F. [4 ]
Gupta, V. [5 ]
Lavie, D. [6 ]
Passamonti, F. [7 ]
Winton, E. F. [8 ]
Dong, H. [9 ]
Kawashima, J. [9 ]
Maltzman, J. D. [9 ]
Kiladjian, J-J. [10 ,11 ]
Harrison, C. N. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Florence, Florence, Italy
[3] Tech Univ, Med Fak Carl Gustav Carus, Dresden, Germany
[4] Univ Barcelona, Hosp Clin, Barcelona, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel
[7] Univ Insubria, Varese, Italy
[8] Emory Univ, Sch Med, Atlanta, GA USA
[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[10] St Louis Hosp, AP HP, Paris, France
[11] Paris Diderot Univ, Paris, France
[12] Guys & St Thomas NHS Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S786
引用
收藏
页码：320 / 321
页数：2
相关论文
共 50 条
  • [1] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    LANCET HAEMATOLOGY, 2018, 5 (02): : E73 - E81
  • [2] Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Cervantes, Francisco
    Gupta, Vikas
    Lavie, David
    Passamonti, Francesco
    Winton, Elliott F.
    Dong, Hua
    Kawashima, Jun
    Maltzman, Julia D.
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
    Harrison, Claire N.
    Vannucchi, Alessandro M.
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez-Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Ellis, Catherine
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    ADVANCES IN THERAPY, 2024, 41 (09) : 3722 - 3735
  • [4] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
    Gotlib, J. R.
    Kiladjian, J-J.
    Catalano, J. V.
    Devos, T.
    Egyed, M.
    Hellman, A.
    McLornan, D. P.
    Shimoda, K.
    Winton, E. F.
    Deng, W.
    Dubowy, R. L.
    Maltzman, J. D.
    Cervantes, F.
    Mesa, R. A.
    HAEMATOLOGICA, 2017, 102 : 320 - 320
  • [5] Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study
    Harrison, Claire N.
    Vannucchi, Alessandro Maria
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Kawashima, Jun
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [6] Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required Red Blood Cell Transfusions: Subgroup Analysis of the Phase 3 SIMPLIFY-2 Study
    Harrison, Claire
    Scheid, Christoph
    Vannucchi, Alessandro M.
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez-Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Kawashima, Jun
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 118
  • [7] Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
    Mesa, Ruben
    Harrison, Claire
    Oh, Stephen T.
    Gerds, Aaron T.
    Gupta, Vikas
    Catalano, John
    Cervantes, Francisco
    Devos, Timothy
    Hus, Marek
    Kiladjian, Jean-Jacques
    Lech-Maranda, Ewa
    McLornan, Donal
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Huang, Mei
    Strouse, Bryan
    Klencke, Barbara
    Verstovsek, Srdan
    LEUKEMIA, 2022, 36 (09) : 2261 - 2268
  • [8] Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
    Ruben Mesa
    Claire Harrison
    Stephen T. Oh
    Aaron T. Gerds
    Vikas Gupta
    John Catalano
    Francisco Cervantes
    Timothy Devos
    Marek Hus
    Jean-Jacques Kiladjian
    Ewa Lech-Maranda
    Donal McLornan
    Alessandro M. Vannucchi
    Uwe Platzbecker
    Mei Huang
    Bryan Strouse
    Barbara Klencke
    Srdan Verstovsek
    Leukemia, 2022, 36 : 2261 - 2268
  • [9] A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
    Vianelli, Nicola
    Benevolo, Giulia
    Vannucchi, Alessandro
    Harrison, Claire N.
    Loschi, Michael
    Al-Ali, Haifa Kathrin
    Bonifacio, Massimiliano
    Cervantes, Francisco
    Wrobel, Tomasz
    Barosi, Giovanni
    Kiladjian, Jean-Jaques
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rose, Shelonitda
    Gharpure, Vishwanath
    Hernandez, Christopher
    Zhang, Jun
    Passamonti, Francesco
    BLOOD, 2021, 138
  • [10] Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
    Gupta, Vikas
    Baer, Maria R.
    Oh, Stephen T.
    Miller, Carole Brennan
    Jun, Susie
    Lee, Peter
    Dong, Hua
    Reiter, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345